Inhibition of mTOR (including mTORC1) with drugs like rapamycin in vitro and in vivo leads to tumor growth arrest and regression in HER2/neu-driven cancer models, further supporting the role of mTORC1 downstream of HER2/neu and upstream of SREBP1. Here, ERBB2 is linked to neoplasm.